Both ALX-0081 and ALX-0681 will be administered in the Phase III TTP trial started yesterday. Ablynx' third in house clinical program, ALX-0141, is a humanized Nanobody that targets the receptor activator for nuclear factor kappa B ligand (RANKL), which is a key regulator of bone metabolism. Ablynx aims to develop ALX-0141 for a range of indications including the treatment of osteoporosis. In September the firm reported positive results from a Phase I safety and pharmacokinetic study with ALX-0141 in healthy postmenopausal women. Ablynx has a number of ongoing Nanobody development collaborations ongoing with partners including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer.